Cost of Insulin Per Month in the U.S.

The same insulin product can cost anywhere from $0 to $400+ per month depending on your insurance status, which programs you’ve enrolled in, and which pharmacy you use. The list below shows what each category of patient actually pays.

Every frequently searched question about insulin costs, answered without hedging or insurance-company-speak.

• 1
  How much is a 30-day supply of insulin? On Medicare: $35 maximum by law · On manufacturer savings programs: $35 for insured and uninsured · At Walmart (ReliOn): $25/vial OTC, no prescription · Uninsured at full cash price: $100–$600+ depending on type and brand

  The honest answer to “how much does insulin cost per month” requires knowing which path you’re on. A 30-day supply at list price for brand-name analog insulins like Humalog or Lantus runs $300–$400+ for a vial, and patients who use multiple vials monthly can theoretically face $600–$900 in full cash costs. These headline numbers are real but not what most insured Americans pay. For Medicare beneficiaries, the Inflation Reduction Act permanently capped monthly insulin copays at $35, regardless of how many vials a patient needs that month. The same $35 cap was voluntarily extended by all three major manufacturers to their own savings programs, covering any insured or uninsured person who registers. At Walmart, the ReliOn line of human insulin (Novolin R, N, and 70/30) is available over-the-counter for $25 per vial without a prescription. This is older human insulin rather than the more modern analog formulations like Humalog, but it has been the financial lifeline for millions of uninsured Americans and remains the fastest, cheapest walk-in option in the country.
• 2
  What is the cheapest insulin available without insurance? Cheapest OTC (no prescription needed): Walmart ReliOn human insulin — $25/vial · Cheapest brand-name analog without insurance: $35/month through manufacturer programs (Lilly, Novo Nordisk, Sanofi all offer this) · Cheapest biosimilar: Mark Cuban Cost Plus Drugs offers Civica biosimilar insulin glargine from $30–$35/vial

  For someone without insurance who needs insulin right now, there are three tiers of options. The fastest is Walmart: walk into any Walmart pharmacy and buy ReliOn human insulin over the counter for $25/vial. No insurance, no prescription, no program enrollment. The limitation is that ReliOn is human insulin (Regular and NPH) rather than the rapid-acting and long-acting analogs that most Type 1 patients and many Type 2 patients are prescribed — switching formulation requires medical guidance because dosing and timing differ. For brand-name modern insulins without insurance, the three major manufacturers all offer $35/month savings cards that require only a 5-minute online registration: Lilly at insulinaffordability.com, Novo Nordisk at myinsulinrx.com, and Sanofi at insulinsavingsus.com. Mark Cuban’s Cost Plus Drugs pharmacy (costplusdrugs.com) offers several insulin products at dramatically lower prices than traditional pharmacies — their transparent pricing model eliminates the pharmacy benefit manager markup that inflates insulin prices everywhere else. GoodRx can also reduce cash prices significantly at participating pharmacies, and the combination of a GoodRx coupon plus the right pharmacy can drop certain generic insulin vials to $30–$50.
• 3
  How much does insulin cost with insurance? Medicare: $35/month maximum by law · Private/employer insurance: $30–$100/month in copays depending on deductible phase and formulary placement · During the deductible phase before insurance kicks in: can be $150–$400/month even with coverage · Manufacturer copay cards reduce private insurance costs further

  The least understood part of insulin pricing is what happens during the insurance deductible phase at the start of each calendar year. Even with solid employer insurance, patients who haven’t yet hit their deductible are paying near-full prices — meaning January through March can be the most expensive months for insulin even for insured patients. This is when manufacturer copay assistance cards are most important: Lilly’s Insulin Value Program, Novo Nordisk’s savings program, and Sanofi’s Valyou Savings all reduce costs for commercially insured patients even while they’re in the deductible phase. These programs are separate from insurance — you use them directly at the pharmacy alongside your insurance, and they reduce your remaining balance. For Medicare specifically, the $35 cap applies across the entire year, including the coverage gap that used to be called the “donut hole.” The gap no longer exists in the way it did before the IRA. Part D plans may vary in how they structure their benefits, but the $35 monthly cap on all covered insulin applies regardless of which phase of the benefit year you’re in.
• 4
  Why does insulin cost so much in the United States? A 1996 vial of Humalog cost $21 — by 2019 it was $275 — a 1,200% increase while overall inflation was 64% · Root causes: no federal drug price negotiation (only recently changed under IRA), pay-for-delay agreements preventing generics, PBM rebate systems that incentivize higher list prices · U.S. insulin prices are 9× higher than in 33 other high-income countries

  The structural reasons behind U.S. insulin prices have been documented extensively by RAND Corporation, the Senate Finance Committee, and academic health economists. Unlike virtually every other developed country, the U.S. had no direct government negotiation of drug prices until the Inflation Reduction Act created limited Medicare negotiating authority. Drug manufacturers could set any list price they chose. Simultaneously, the rebate system created by pharmacy benefit managers (PBMs) inadvertently incentivized higher list prices — manufacturers set prices high, offered large rebates to PBMs, who then gave formulary placement to high-list-price drugs, creating a cycle that pushed prices upward. “Pay-for-delay” agreements, where brand-name manufacturers pay generic competitors to delay entering the market, kept competition out for years. Three manufacturers — Eli Lilly, Novo Nordisk, and Sanofi — produce the vast majority of U.S. insulin, creating an oligopoly with little competitive pressure. According to a RAND study, U.S. insulin prices even after accounting for rebates remain 2.3 times higher than in comparison nations. The price of a single product (Humalog) increased 1,200% between 1996 and 2019 while inflation rose only 64% — not because of improved product or manufacturing costs, but because the market structure permitted it.
• 5
  How much does insulin cost in other countries? Germany: ~$11 per vial · Canada: ~$32 per vial · France: ~$8 per vial · United Kingdom (NHS): £0 with prescription · U.S. list price: $100–$400+ per vial · U.S. prices are 5–10× higher than in comparable nations · Some Americans travel to Canada or Mexico to buy insulin at lower prices

  The international comparison is stark and widely documented. A vial of Humalog that costs $274 at a U.S. pharmacy without savings programs costs approximately $32 in Canada, $11 in Germany, and $8 in France — for the same product from the same manufacturer. In the UK, insulin is free with a prescription under the NHS. A RAND analysis found that U.S. gross insulin prices are more than nine times higher than in 33 comparison high-income nations. Even accounting for U.S. rebates that reduce what insurers pay, the net price in the U.S. remains 2.3 times higher. This disparity is why insulin tourism — Americans crossing into Canada or Mexico to purchase insulin at local prices — became a recurring news story. The practice is technically legal for personal-use quantities and is documented in studies from academic journals and government health agencies. Some advocacy groups organize bus trips to Canadian pharmacies specifically for insulin purchasing. The Inflation Reduction Act changed the Medicare picture significantly, but the U.S. still pays far more than any comparable country for the same vials.
• 6
  What are biosimilar insulins and are they safe? Biosimilars are FDA-approved “generic equivalents” of brand-name biologic drugs · The FDA confirms biosimilars have no clinically meaningful differences in safety, purity, or potency from the reference product · Cost 15–30% less than brand-name insulin · Several are now FDA-approved and available including Semglee (interchangeable with Lantus) and Rezvoglar

  Insulin is classified as a biologic drug — it’s a protein produced through complex biological manufacturing rather than simple chemical synthesis, which is why it took longer than typical drugs to get “generic” versions. The FDA’s biosimilar pathway, established under the Biologics Price Competition and Innovation Act, requires manufacturers to demonstrate no clinically meaningful differences from the reference (brand-name) product in terms of safety, purity, and potency. An FDA-designated “interchangeable” biosimilar (the highest approval level) can be substituted for the brand-name product at the pharmacy without a new prescription from your doctor — exactly like a generic drug. Semglee (biosimilar for Lantus/insulin glargine) became the first FDA-designated interchangeable insulin biosimilar and is available at pharmacies now. Rezvoglar is another. California’s CalRx is also a biosimilar insulin glargine. These products typically cost 15–30% less than their brand-name equivalents, and with GoodRx coupons or savings programs, can be even cheaper. Ask your pharmacist whether your current insulin has an approved interchangeable biosimilar — switching requires no doctor’s visit in most states and can immediately lower your cost.
• 7
  How many vials of insulin does the average person need per month? Type 1 diabetes: typically 2–4 vials per month · Type 2 on insulin therapy: typically 1–3 vials per month · Varies widely based on body weight, activity level, and blood sugar control · People using insulin pens: equivalent consumption but different format

  The number of vials a person uses monthly varies significantly by diabetes type, individual physiology, treatment regimen, and blood sugar management. A typical Type 1 patient on a basal-bolus regimen (a long-acting insulin once daily plus a rapid-acting insulin with meals) might use one vial of each type per month — or more if their doses are higher. People with greater insulin resistance (common in Type 2) or those managing less well-controlled blood sugar levels generally use more. Vials contain 1,000 units (10 mL at 100 units/mL). A person taking 50 units daily of one insulin would use 1,500 units per month — requiring 1.5 vials. Someone taking 80 units daily of basal plus variable bolus doses might need 3–5 vials monthly. Insulin pens contain 300 units (3 mL) and come in packs of 5, making comparisons slightly different — 5 pens equal 1,500 units, roughly what one to two vials provide. This vial math matters for budgeting: the $35 monthly program caps apply per person regardless of how many vials they use, making them far more valuable for patients who require larger quantities.
• 8
  I am on a fixed income and cannot afford insulin — what are my options? Step 1: Call the manufacturer’s patient assistance line — income up to 400% FPL (~$60,240/year) qualifies for free insulin · Step 2: Apply to a community health center (340B clinic) for income-based pricing · Step 3: Check your state — 20+ states have copay caps between $25–$100 · Step 4: Use Mark Cuban Cost Plus Drugs or GoodRx for lowest cash prices · Never ration insulin — call the manufacturer first

  For patients on fixed incomes — Social Security, retirement, disability — three paths reliably reach $0 to $35 per month. Manufacturer Patient Assistance Programs (PAPs) provide insulin free of charge to patients whose income is at or below 400% of the federal poverty level, which in 2026 is approximately $60,240/year for a single person or $124,800 for a family of four. These programs are Lilly Cares Foundation (lillycares.com), Novo Nordisk Patient Assistance Program (novonordiskus.com/pap), and Sanofi Patient Connection (sanofi.us/media/pdf/patient-connection). Applications take roughly 15–30 minutes online and often deliver a 90–120 day supply of free insulin by mail within two weeks. Federally Qualified Health Centers (FQHCs) — also called 340B clinics — receive drugs at dramatically reduced prices under a federal program designed for underserved patients. If you live near one, you may access significantly reduced or sliding-scale insulin pricing regardless of insurance status. Find your nearest FQHC at findahealthcenter.hrsa.gov. For Medicare patients on low incomes, the Extra Help program (also called Low Income Subsidy, or LIS) further reduces prescription costs beyond the $35 cap — apply through Social Security at ssa.gov/i1020.

Use the buttons below to find community health centers with income-based insulin pricing, local pharmacies, or Medicare counseling services near you.